Researchers in India have designed a synthetic molecule that kills MRSA by hitting an enzyme that conventional antibiotics have always left alone.
In 1928, Alexander Fleming came back from holiday to find a rogue mold had dissolved the bacteria on one of his petri dishes. That happy accident gave humanity penicillin — and one of its first conquests was Staphylococcus aureus. Nearly a century later, the same bacterium is on the World Health Organization's list of the most dangerous superbugs on Earth. The organism has learned, spectacularly, to fight back.
Methicillin-resistant S. aureus — MRSA — is the "S" in ESKAPE, a grim shortlist of six pathogens notorious for shrugging off multiple antibiotics. It infects skin, bloodstreams, and surgical implants. According to the 2024 GRAM report in The Lancet, drug-resistant infections could directly kill more than 39 million people between 2025 and 2050, with resistant Staphylococcus strains linked to roughly 130,000 deaths.
South Asia alone is expected to bear about 11.8 million of those deaths — a staggering and deeply unequal burden. Now, a research team at the Indian Institute of Technology Gandhinagar (IITGN) thinks it has found a genuinely new way to fight back. Their study, published in Chemistry & Biodiversity, describes a laboratory-made molecule that disables an enzyme called thymidine kinase (TK) — a target that most existing antibiotics have never bothered to attack.
Most drugs work by punching holes in bacterial walls or jamming protein-making machinery, routes that MRSA has spent decades learning to dodge.